Butler and colleagues identified and characterized a new class of small molecule ERG antagonists through rational in silico methods, demonstrating that a small molecule targeting the ERG-ETS domain suppressed its transcriptional activity and reverse transformed the characteristics of prostate cancers aberrantly expressing ERG (Butler et al., 2017). The gene discussed is ERG; the disease is prostate cancer.